FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
Trumpcare receives a blow; EMA to suspend 300 drugs due to clinical data integrity violations in India
This week, Phispers takes you to the US, where President Trump’s efforts to repeal and replace